Overview of Prohibit

Property	Description
Active Ingredient	Levamisole (as levamisole hydrochloride)
Form	Soluble Drench Powder
Pharmacological Class	Anthelmintic (Imidazothiazole subgroup)
Common Use	Treating parasitic worm infections (roundworms)
Origin	Synthetic Chemical

What is Prohibit and What is its Purpose?

Prohibit is the trade name for a veterinary medicine whose active component is used to manage infections caused by parasitic worms in livestock. It is classified as an anthelmintic, a drug category specifically intended to expel or destroy helminths (worms) from the body.

The drug's general purpose is to provide a targeted solution for managing parasitic burdens, particularly gastrointestinal and pulmonary roundworm infections. Levamisole is recognized for its efficacy as a potent anthelmintic agent against susceptible nematodes in ruminants. This means the drug has been recognized for its ability to clear certain parasitic worms in animals.

What is the Active Ingredient in Prohibit?

The single active ingredient in Prohibit is Levamisole, typically present as levamisole hydrochloride. Levamisole is a synthetic chemical compound developed specifically for its anti-worm activity, ensuring a predictable level of potency compared to preparations derived from natural extracts.

As a single-ingredient preparation, Prohibit relies solely on the action of Levamisole. Levamisole acts by selectively inhibiting nerve transmission in the parasite, causing rapid paralysis.

What is Prohibit Soluble Drench Powder?

Prohibit is supplied in the physical form of a Soluble Drench Powder. This specific formulation is a key differentiating factor, providing ease of bulk storage and allowing the user to prepare a liquid solution on-site via the Oral route. This liquid is given directly to the animal as a drench. This dosage form supports the drug's rapid paralytic mechanism, leading to the efficient expulsion of the parasites.

Regulatory References

What side effects are possible with Prohibit?

Possible Side Effects and Safety Information

The official safety documentation for Prohibit (Levamisole) outlines specific adverse reactions observed in the target animal species, alongside critical safety constraints for handlers. When administered to cattle and sheep at the recommended dose, adverse reactions are officially classified as rare.

Adverse Reaction Groupings

The documented effects primarily fall into two System-Organ Classes as defined by regulatory labeling:

Nervous System Disorders: Reactions may include slight muscle tremors and signs of impaired motor function.
Gastrointestinal Disorders: Reactions can involve excessive salivation (hypersalivation) and the appearance of muzzle foam.

These reactions, particularly at higher dosages, are generally described as transient (short-lived). However, a persistent cough may be observed following successful treatment of lungworm infections, which is attributed to residual tissue damage caused by the parasites.

Safety Considerations and Limitations

The product label includes specific constraints for use in special physiological states, noting that caution is required when administering the medicine to severely debilitated animals or those under physiological stress.

Serious Safety Limitations: The regulatory documentation explicitly states that the product is NOT FOR USE IN HUMANS. Furthermore, the label mandates a contraindication against concurrent use with specific agents, such as organophosphates, to avoid the risk of enhanced toxic effects. Human exposure warnings note the potential for the active ingredient to cause serious blood disorders.

Overdose and Emergency Response

Overdose and when to seek help

The following information details the officially documented acute toxicity profile and mandated emergency actions for Levamisole, the active ingredient in Prohibit, as described in authoritative governmental regulatory sources.

Documented Overdose Manifestations

Acute overexposure is associated with severe neuro-cholinergic toxicity affecting the central nervous system, autonomic functions, and gastrointestinal system. Documented clinical signs include muscle tremors, convulsions (seizures), ataxia (loss of coordination), and extreme irritability or agitation.

Severe Outcomes and Emergency Actions

The toxicity is classified as acute and potentially severe, with risks including physical collapse, prostration, and respiratory distress (dyspnea). Regulatory guidance mandates that if overdose or overexposure is suspected, an individual must immediately call a POISON CENTER/doctor or seek medical advice immediately for persistent symptoms.

Official Management and Antidote Status

Official prescribing information confirms that no specific antidote is known for Levamisole toxicity. Management principles are strictly confined to symptomatic and supportive treatment, requiring close observation and management of the severe clinical signs. Procedurally, for ingestion, regulatory guidance requires the mouth be rinsed, and instructs DO NOT induce vomiting.

Therapeutic Uses of Prohibit

What Prohibit Treats: Main Uses and Benefits

Prohibit is an anthelmintic agent primarily utilized in veterinary medicine and is applied in addressing nematode infections in livestock. It is commonly used to help with various parasitic roundworms, including those affecting both the gastrointestinal tract and the lungs.

The medication is commonly used for managing conditions characterized by systemic or localized discomfort caused by the parasitic presence. These conditions include gastrointestinal roundworm infections (such as Haemonchus spp. and Ostertagia spp.), pulmonary roundworm infections (Dictyocaulus spp.), and situations involving heavy or chronic parasitic burdens leading to physiological decline.

Following application, the medication assists with managing symptoms related to systemic imbalance (like severe weight loss and poor growth rate) and is relevant for easing symptoms that interfere with daily comfort, such as persistent coughing and labored breathing. This supportive relief may assist with maintaining functional stability.

“The use of Levamisole is relevant when supportive symptom management is appropriate in conditions marked by increased physiological stress.”

Quick Fact: Support for Physiological Decline

The treatment is commonly used in contexts marked by increased physiological stress, helping to manage symptoms related to parasite-induced physiological decline and supporting general well-being during symptomatic phases.

Regulatory References

FDA-Approved Indications for Levamisole Hydrochloride

Eligibility and Restrictions for Use

Prohibit is a veterinary medicine whose population eligibility is strictly defined by regulatory authorities, focusing on target species and specific physiological conditions. The medicine is formally allowed for use in Cattle and Sheep only.

Populations for Whom Use is Contraindicated

Regulatory labeling specifies absolute prohibitions for several groups:

Humans: The label states an absolute prohibition: NOT FOR USE IN HUMANS.
Dairy Animals of Breeding Age: Administration is strictly prohibited to prevent drug residues in milk intended for human consumption.
Impaired Hepatic Function: Use is contraindicated in animals with pre-existing liver impairment.
Known Hypersensitivity: Contraindicated in animals with a known allergy to Levamisole.

Eligibility-Related Restrictions

Use requires caution or veterinary consultation for animals in the following conditional states:

Severely Debilitated Animals: Use must be preceded by consultation with a veterinarian.
Physiological Stress: Caution is necessary when treating animals that are heavily pregnant or under stress (e.g., poor nutrition, adverse weather).
Renal Impairment: Treatment should be administered with caution in animals with kidney issues.

Eligibility is determined by body weight for accurate dose calculation, not by age-based thresholds.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Prohibit (Levamisole) is defined by established regulatory documentation, which outlines strict drug-drug constraints primarily in the categories of pharmacodynamic (PD) and pharmacokinetic (PK) interactions.

Formally Prohibited Combinations and Timing Rules

Certain co-administrations are strictly contraindicated due to the risk of Pharmacodynamic Reinforcement, resulting in additive toxicity. These prohibited substances include Organophosphate compounds (such as coumaphos or trichlorfon) and Diethylcarbamazine. Regulatory labeling strictly requires that these compounds must not be administered within a period of 14 days either preceding or following treatment with Levamisole. This mandatory separation period is essential to prevent synergistic toxic effects. Other medicinal products classified as cholinergic agonists may also produce an additive PD effect, which increases the documented risk of toxicity.

Exposure-Altering Interactions

The product's pharmacokinetic profile is subject to alteration by specific agents. Regulatory records indicate that substances such as Cimetidine and Dexamethasone may reduce the clearance of Levamisole. This particular pharmacokinetic interaction can result in increased plasma concentrations of Levamisole and a subsequent prolongation of its systemic exposure.

Mechanism of Action

How Prohibit Works

The pharmacodynamic action of Prohibit (Levamisole) involves the disruption of the neuromuscular signaling of the parasitic worm.

Selective Agonism of Parasite Nicotinic Receptors

Prohibit operates by acting as a highly selective agonist on the Nicotinic Acetylcholine Receptors ( nAChRs) found exclusively on the somatic muscle cells of susceptible nematodes. By activating these specific receptors, the drug immediately initiates an uncontrolled ion influx, overriding the worm's normal neuromuscular transmission.

Induction of Spastic Paralysis

This overwhelming molecular activation triggers a state of depolarizing neuromuscular blockade, inducing the parasite’s body musculature to enter a state of persistent, rigid contraction, which is defined as spastic paralysis. This physiological effect results in the worm's loss of motile function and attachment capability. Functional incapacitation by paralysis is the prerequisite for the worm's passive expulsion.

Mechanism Constraints and Life Stage Specificity

The mechanism is observed to be highly functional against the adult stage of the parasite, where the target receptors are fully expressed and accessible. However, the physiological consequence of this mechanism is reduced or limited against larval stages or tissue-encysted forms, and may be weakened by the presence of Levamisole-resistant receptor subtypes in some parasite populations.

Dosage and Administration Information

How Prohibit is Used: Official Administration Guidelines

The usage of Prohibit (levamisole hydrochloride) follows a procedural approach focused on accurate, weight-based administration.

Administration Protocol

The dosage form is a Soluble Drench Powder, which requires on-site reconstitution into a liquid solution before use. The route of administration for this form is oral, delivered as a drench.

Feature	Official Labeled Instruction
Dosing Schedule	A single dose of 8 mg of levamisole per kilogram (mg/kg) of body weight is used for cattle and sheep.
Preparation	The powder must be dissolved in a specified volume of water to create the drench solution. For a standard cattle drench, a 52 g packet is mixed with 1 quart of water; for sheep, the same packet is mixed with 1 gallon.
Frequency	The product is generally administered as a single oral dose. Conditional retreatment may be necessary 2 to 4 weeks after the initial dose if the animals remain under conditions of constant helminth exposure.

Procedural Requirements

Official step sequence:

The most critical instruction is the accurate determination of the animal's current body weight to calculate the correct volume for the 8 mg/kg dose.
The powder is diluted according to the specific instructions on the packet to produce the standard or concentrated drench solution.
The calculated single dose is administered orally using appropriate drenching equipment.

These instructions structure the use of the drug as a short-term intervention where the calculated dose is dependent entirely on the animal’s weight. The requirement for on-site dilution and the single-dose nature of the therapy are foundational to the administration protocol. Prepared drench solution that is not immediately used may be stored for up to 90 days in a closed container, provided it is shaken well before subsequent use.

Recent Clinical Evidence

Research evidence / Overview of studies for Prohibit

Evidence for Gastrointestinal and Pulmonary Nematode Infections

Research conducted for regulatory purposes and subsequent field assessments focused on Levamisole's use in conditions characterized by gastrointestinal and pulmonary roundworm infections in livestock. These studies typically involved controlled efficacy trials where the response of treated animal groups was compared to that of untreated control groups. The research explored how parasite presence was measured during defined time intervals to understand short-term clearance patterns.

The primary outcomes examined in these studies were quantitative metrics of parasite burden. Researchers primarily tracked two key outcomes: the reduction in Faecal Egg Count (FECR) and, in certain controlled settings, the reduction in worm burdens through direct count. The reported findings contribute to the broader evidence landscape by describing how parasite populations evolved in the observed animals during the study period.

Studies in Target Ruminant Populations

The available evidence explored Levamisole's action across its primary target species, which include large ruminants like cattle and smaller ruminants such as sheep and goats. Studies monitored animals with both naturally acquired and experimentally induced infections to gather evidence across varying symptom burdens. Research was applied in contexts involving fluctuating or unstable symptoms often associated with parasitic presence. The design and parameters of these studies focused on monitoring parasite presence in these specific livestock groups.

Follow-up Research on Durability and Resistance

Research describes that while initial controlled trials explored metrics of short-term parasite clearance, extensive long-term observational studies have also been conducted globally. These studies primarily monitored the patterns associated with parasite presence over time.

Key Research Gaps and Areas of Uncertainty

Research provides context but not individual predictions, and certain gaps remain in the scientific understanding. The follow-up durations were limited in many initial efficacy trials, meaning long-term effects are not fully established regarding the long-term parasite control patterns. Data for optimal resistance management strategies remain insufficient, suggesting that research is ongoing to address the complexities of parasite evolution and management.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Prohibit (FAQ)

Q: Does Prohibit work immediately, or does it take a few days to feel the effects?

Official information indicates that Prohibit's mechanism of action is rapid. It works by causing an immediate activation and paralysis of the parasite's nervous system. The rapid mechanism of action leads to the eventual expulsion of the paralyzed parasites.

Q: How long does Prohibit stay active in your system?

The active component, Levamisole, is reported to have a relatively short elimination half-life in mammals (around 3 to 4 hours). For its approved veterinary use, the label requires a strict withdrawal period to ensure residues are below acceptable tolerance levels before the animal can be used for food purposes.

Q: Do the side effects of Prohibit usually go away after a while?

Yes, official safety documentation states that adverse reactions observed in the target animal species are generally described as transient, meaning they are short-lived. If any reaction seems severe or persistent, handlers should refer to the specific safety instructions provided on the product label.

Q: Is it normal to feel nauseous or dizzy when first starting Prohibit?

The adverse reactions documented in the target species (cattle and sheep) do not include nausea or dizziness. The most commonly reported signs in animals are nervous system reactions such as slight muscle tremors and impaired motor function, along with excessive salivation.

Q: Does Prohibit interact with alcohol?

Prohibit is a veterinary medicine and is strictly NOT FOR USE IN HUMANS. However, the active ingredient, Levamisole, has been associated in human studies with a moderate interaction with alcohol that can intensify certain side effects. This information reinforces the strict warning that Prohibit is NOT FOR USE IN HUMANS.

Q: Is Prohibit a controlled substance?

No. The active component, Levamisole, is classified as an Anthelmintic drug and is not currently listed as a DEA controlled substance.

Q: Does Prohibit need a specific withdrawal plan?

Yes, for its approved use in livestock, the veterinary product label requires a withdrawal period (a specific time frame after treatment) before the animal can be slaughtered for human consumption. This is required to prevent drug residues in the food supply.

Q: What makes Prohibit different from older drugs used for similar conditions?

Prohibit’s active ingredient belongs to the Imidazothiazole class of anthelmintics. This class is characterized by its specific mechanism of action: selectively acting on the parasite's nervous system to cause spastic paralysis, distinguishing it pharmacologically from some older drug classes.

Q: How long after taking Prohibit is it safe to take a drug that might interact?

For specifically contraindicated drugs, such as Organophosphates, the product label mandates a strict separation period of 14 days. These compounds must not be administered within 14 days preceding or following treatment with Prohibit to avoid enhanced toxic effects.

Q: What are the signs that Prohibit might not be working for me?

Failure to see improvement in the animal's condition or continued evidence of parasitic presence would require a veterinary assessment. The primary measure of effectiveness tracked in studies is the reduction in Faecal Egg Count (FECR).

Q: Does Prohibit have a cumulative effect over time?

Prohibit is administered as a single dose and has a rapid, short-lived paralyzing mechanism. Its rapid, paralyzing mechanism suggests a non-cumulative function. Conditional retreatment is only recommended after 2 to 4 weeks under specific conditions.

Q: Are there different strengths or forms of Prohibit available?

The product is supplied in the physical form of a Soluble Drench Powder. This powder is designed to be reconstituted on-site into a liquid solution before administration. Dosing strength is customized based on the body weight of the animal being treated.

Q: Can Prohibit cause stomach ulcers or irritation?

The documented gastrointestinal side effects are primarily limited to excessive salivation and muzzle foam. Stomach ulcers or general severe irritation are not listed among the documented adverse reactions in the target animal species.

Q: What is the consensus among medical professionals about Prohibit?

Regulatory bodies and research indicate that the active component, Levamisole, is clinically recognized by authorities like the EMA as a potent and effective anthelmintic agent. It is approved for use against susceptible nematodes in ruminants.

Q: Can I use Prohibit if my animal has kidney issues?

Official information states that use requires caution when treating animals with pre-existing renal (kidney) impairment. A veterinary consultation is necessary for making treatment decisions.

Q: Can children or teenagers take Prohibit?

Prohibit is a veterinary medicine and the product label carries an absolute prohibition: NOT FOR USE IN HUMANS. This critical safety warning applies to all human age groups, including children and teenagers.

Q: How soon after starting Prohibit should I expect an improvement?

The drug's mechanism is rapid-acting, and research focuses on short-term clearance patterns following treatment. While individual responses can vary, the drug’s rapid mechanism of action suggests that the initial effects (paralysis and expulsion of parasites) are expected to occur quickly after administration.

How should Prohibit be stored and disposed of?

How to Store and Dispose of Prohibit?

Official regulatory documents define strict requirements for the storage and disposal of Prohibit (Levamisole Soluble Drench Powder).

Storage Conditions

The powder must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F), and protected from direct sunlight in a cool, dry place. Containers must be kept tightly closed when not in use. The reconstituted solution is stable for up to 90 days when stored in clean closed containers at or below 25 C.

Disposal and Safety

The product label mandates that Prohibit must be kept out of reach of children and stored locked up. Disposal of unused product and containers must occur via an approved waste disposal plant in compliance with all Federal, State, and local regulations. It is strictly required to avoid release to the environment and prevent the product from entering drains.

Prohibit